16-Week Data From SALWEEN Fill the Gap for Patients With PCV - Top_Thought_Leaders - MDSpire

16-Week Data From SALWEEN Fill the Gap for Patients With PCV

Discover insights from Professor Gemmy Cheung as she discusses the promising first-time data from the SALWEEN study on the use of faricimab in patients with polypoidal choroidal vasculopathy (PCV).

  • By

  • Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

  • Michael A. Singer, MD

  • March 1, 2025

  • 9 min

Share

Top Thought Leaders in Ophthalmology

Brief introduction explaining scope and methodology.

Original Source(s)

16-Week Data From SALWEEN Fill the Gap for Patients With PCV

  • by Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI, Michael A. Singer, MD

  • March 1, 2025

Related Content

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it. 

New Product Applications: Glasses Offer Vision Enhancement With a Virtual Assistant

Two doctors have developed a groundbreaking wearable vision aid using AI technology to help individuals with low vision navigate daily activities, offering features such as a multimedia AI-powered assistant and lightweight, intuitive design.